Proposed takeover of AstraZeneca
14 May 2014
In this one-off evidence session, the Science and Technology Committee considers the potential impact on the UK science base of a merger between the pharmaceutical companies AstraZeneca and Pfizer.
- Parliament TV: Watch the evidence session on the proposed takeover of AstraZeneca
- Inquiry: Proposed takeover of AstraZeneca
- Science and Technology Committee
The Committee will take evidence from both companies and from the Minister for Universities and Science, David Willetts MP.
Witnesses
Wednesday 14 May 2014; Thatcher Room, Portcullis House
At 9.15 am
- Dr Mikael Dolsten, President, Worldwide Research and Development, Pfizer
- Dr Rod MacKenzie, Group Senior Vice President, and Head of Pfizer PharmaTherapeutics Research and Development, Pfizer
- Ian C. Read, Chairman of the Board and Chief Executive Officer, Pfizer
At 9.45 am
- Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca plc
- Dr Mene Pangalos, Executive Vice President, Innovative Medicines and Early Development, AstraZeneca plc
- Dr Jane Osbourn, Vice President Research and Development and Site Leader MedImmune Cambridge (UK), AstraZeneca plc
At 10.15 am
- Rt Hon David Willetts MP, Minister of State for Universities and Science, Department for Business, Innovation and Skills
Committee Chair
Andrew Miller MP, Chair of the Science and Technology Committee, said:
"AstraZeneca is one of the bastions of the UK’s world-leading pharmaceutical sector. It supports around 30,000 jobs, many of them highly skilled, and is an important component of our scientific landscape. Next week’s hearing will be an opportunity for us to scrutinise the pledges on research and development being made as part of this potential takeover and pose questions about how the Government will ensure that these commitments are met."